In a 30 week , double-blind , randomized , controlled Phase 3 study in patients with type 2 diabetes mellitus , the addition of fixed-dose exenatide twice daily ( BID ) to titrated insulin glargine resulted in significant glycated hemoglobin ( HbA ( 1c ) ) lowering and weight loss without increased hypoglycemia risk versus titrated insulin glargine alone .